Acyl-CoA Binding Domain Containing 4 Polymorphism rs4986172 and Expression Can Serve as Overall Survival Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Hepatectomy

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Xu L, Qian G, Tang L, Su J, Wang JS. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. J Hepatol. 2010;53(4):671–676. doi:10.1016/j.jhep.2010.04.032
   PubMed Web of Science ®Google Scholar
• Qi LN, Li LQ, Chen YY, et al. Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China. PLoS One. 2013;8(12):e83465. doi:10.1371/journal.pone.0083465
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-1
   PubMed Web of Science ®Google Scholar
• Bishop A, Kamoshita M, Passmore JB, et al. Fluorescent tools to analyse peroxisome-ER interactions in mammalian cells. Contact. 2019;2:2515256419848641. doi:10.1177/2515256419848641
   Google Scholar
• Costello JL, Castro IG, Schrader TA, Islinger M, Schrader M. Peroxisomal ACBD4 interacts with VAPB and promotes ER-peroxisome associations. Cell Cycle. 2017;16(11):1039–1045. doi:10.1080/15384101.2017.1314422
   PubMed Web of Science ®Google Scholar
• Adriaens ME, Lodder EM, Moreno-Moral A, et al. Systems genetics approaches in rat identify novel genes and gene networks associated with cardiac conduction. J Am Heart Assoc. 2018;7(21):e009243. doi:10.1161/JAHA.118.009243
   PubMed Web of Science ®Google Scholar
• Liao JM, Zeng SX, Zhou X, Lu H. Global effect of inauhzin on human p53-responsive transcriptome. PLoS One. 2012;7(12):e52172. doi:10.1371/journal.pone.0052172
   PubMed Web of Science ®Google Scholar
• Consortium GT, Thomas J, Salvatore M. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–585. doi:10.1038/ng.2653
   PubMed Web of Science ®Google Scholar
• Sun Y, Ji F, Kumar MR, et al. Transcriptome integration analysis in hepatocellular carcinoma reveals discordant intronic miRNA-host gene pairs in expression. Int J Biol Sci. 2017;13(11):1438–1449. doi:10.7150/ijbs.20836
   PubMed Web of Science ®Google Scholar
• Lu Y, Xu W, Ji J, et al. Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. Hepatology. 2015;62(4):1122–1131. doi:10.1002/hep.27923
   PubMed Web of Science ®Google Scholar
• Chen S, Fang H, Li J, et al. Microarray analysis for expression profiles of lncRNAs and circRNAs in rat liver after brain-dead donor liver transplantation. Biomed Res Int. 2019;2019:5604843. doi:10.1155/2019/5604843
   PubMed Web of Science ®Google Scholar
• Zhao X, Parpart S, Takai A, et al. Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. Oncogene. 2015;34(39):5095–5104. doi:10.1038/onc.2014.438
   PubMed Web of Science ®Google Scholar
• Roessler S, Long EL, Budhu A, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142(4):957–966 e912. doi:10.1053/j.gastro.2011.12.039
   PubMed Web of Science ®Google Scholar
• Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202–10212. doi:10.1158/0008-5472.CAN-10-2607
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao B, Tan PY, et al. Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth. FASEB J. 2019;33(8):8759–8770. doi:10.1096/fj.201802213RR
   PubMed Web of Science ®Google Scholar
• Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5(12):181006. doi:10.1098/rsos.181006
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765–769. doi:10.1038/ng.2295
   PubMed Web of Science ®Google Scholar
• Srivastava S, Wong KF, Ong CW, et al. A morpho-molecular prognostic model for hepatocellular carcinoma. Br J Cancer. 2012;107(2):334–339. doi:10.1038/bjc.2012.230
   PubMed Web of Science ®Google Scholar
• Ivanovska I, Zhang C, Liu AM, et al. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One. 2011;6(9):e24582. doi:10.1371/journal.pone.0024582
   PubMed Web of Science ®Google Scholar
• Lim HY, Sohn I, Deng S, et al. Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol. 2013;20(12):3747–3753. doi:10.1245/s10434-013-3070-y
   PubMed Web of Science ®Google Scholar
• Cho YA, Choi S, Park S, Park CK, Ha SY. Expression of pregnancy up-regulated non-ubiquitous calmodulin kinase (PNCK) in hepatocellular carcinoma. Cancer Genomics Proteomics. 2020;17(6):747–755. doi:10.21873/cgp.20229
   PubMed Web of Science ®Google Scholar
• Ha SY, Sohn I, Hwang SH, Yang JW, Park CK. The prognosis of hepatocellular carcinoma after curative hepatectomy in young patients. Oncotarget. 2015;6(21):18664–18673. doi:10.18632/oncotarget.4330
   PubMedGoogle Scholar
• Dituri F, Scialpi R, Schmidt TA, et al. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro. Cell Death Dis. 2020;11(11):984. doi:10.1038/s41419-020-03180-8
   PubMed Web of Science ®Google Scholar
• Zubiete-Franco I, Garcia-Rodriguez JL, Lopitz-Otsoa F, et al. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer. EBioMedicine. 2019;40:406–421. doi:10.1016/j.ebiom.2018.12.031
   PubMed Web of Science ®Google Scholar
• Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2016;65(5):861–869. doi:10.1136/gutjnl-2014-308483
   PubMed Web of Science ®Google Scholar
• Makowska Z, Boldanova T, Adametz D, et al. Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma. J Pathol Clin Res. 2016;2(2):80–92. doi:10.1002/cjp2.37
   PubMedGoogle Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–1935. doi:10.1126/science.1132939
   PubMed Web of Science ®Google Scholar
• Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer. 2007;7(1):54–60. doi:10.1038/nrc2044
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44(D1):D380–384. doi:10.1093/nar/gkv1277
   PubMed Web of Science ®Google Scholar
• Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2008;36(Databaseissue):D684–688. doi:10.1093/nar/gkm795
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Nekvindova J, Mrkvicova A, Zubanova V, et al. Hepatocellular carcinoma: gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochem Pharmacol. 2020;177:113912. doi:10.1016/j.bcp.2020.113912
   PubMed Web of Science ®Google Scholar
• Liu ZZ, Yan LN, Dong CN, et al. Cytochrome P450 family members are associated with fast-growing hepatocellular carcinoma and patient survival: an integrated analysis of gene expression profiles. Saudi J Gastroenterol. 2019;25(3):167–175. doi:10.4103/sjg.SJG_290_18
   PubMed Web of Science ®Google Scholar
• Wang JF, Chou KC. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab. 2010;11(4):342–346. doi:10.2174/138920010791514180
   PubMed Web of Science ®Google Scholar
• Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clin Liver Dis. 2017;21(1):1–20. doi:10.1016/j.cld.2016.08.001
   PubMed Web of Science ®Google Scholar
• Tian Q, Wang L, Sun X, Zeng F, Pan Q, Xue M. Scopoletin exerts anticancer effects on human cervical cancer cell lines by triggering apoptosis, cell cycle arrest, inhibition of cell invasion and PI3K/AKT signalling pathway. J BUON. 2019;24(3):997–1002.
   PubMed Web of Science ®Google Scholar
• Yuan C, Wang MH, Wang F, et al. Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer. Life Sci. 2021;270:119105. doi:10.1016/j.lfs.2021.119105
   PubMed Web of Science ®Google Scholar
• Manuele MG, Ferraro G, Barreiro Arcos ML, Lopez P, Cremaschi G, Anesini C. Comparative immunomodulatory effect of scopoletin on tumoral and normal lymphocytes. Life Sci. 2006;79(21):2043–2048. doi:10.1016/j.lfs.2006.06.045
   PubMed Web of Science ®Google Scholar
• Seo EJ, Saeed M, Law BY, et al. Pharmacogenomics of scopoletin in tumor cells. Molecules. 2016;21(4):496. doi:10.3390/molecules21040496
   PubMed Web of Science ®Google Scholar
• Sun H, Zheng X, Zhou Y, et al. Alphaxalone inhibits growth, migration and invasion of rat C6 malignant glioma cells. Steroids. 2013;78(10):1041–1045. doi:10.1016/j.steroids.2013.06.008
   PubMed Web of Science ®Google Scholar
• Hagmann W, Borgers S. Requirement for epidermal growth factor receptor tyrosine kinase and for 12-lipoxygenase activity in the expression of 12-lipoxygenase in human epidermoid carcinoma cells. Biochem Pharmacol. 1997;53(7):937–942. doi:10.1016/S0006-2952(96)00833-7
   PubMed Web of Science ®Google Scholar
• Dinney CP, Parker C, Dong Z, et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res. 1997;3(2):161–168.
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhang B, Sun Y, et al. Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis. Onco Targets Ther. 2019;12:3545–3563. doi:10.2147/OTT.S198621
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhao Z, Shang J, Xia W. Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach. J Diabetes Res. 2014;2014:763936. doi:10.1155/2014/763936
   PubMed Web of Science ®Google Scholar
• Funai K, Honzawa K, Suzuki M, et al. Urinary fluorescent metabolite O-aminohippuric acid is a useful biomarker for lung cancer detection. Metabolomics. 2020;16(10):101. doi:10.1007/s11306-020-01721-y
   PubMed Web of Science ®Google Scholar
• Snyder S, Murundi S, Crawford L, Putnam D. Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate. J Control Release. 2020;317:291–299. doi:10.1016/j.jconrel.2019.11.027
   PubMed Web of Science ®Google Scholar
• Jones RD, Kerr DJ, Harnett AN, Rankin EM, Ray S, Kaye SB. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer. 1990;62(1):133–135. doi:10.1038/bjc.1990.244
   PubMed Web of Science ®Google Scholar
• Wishart GC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol. 1994;12(9):1771–1777. doi:10.1200/JCO.1994.12.9.1771
   PubMed Web of Science ®Google Scholar
• Melkoumian ZK, Martirosyan AR, Strobl JS. Myc protein is differentially sensitive to quinidine in tumor versus immortalized breast epithelial cell lines. Int J Cancer. 2002;102(1):60–69. doi:10.1002/ijc.10648
   PubMed Web of Science ®Google Scholar
• Ru Q, Tian X, Pi MS, et al. Voltagegated K+ channel blocker quinidine inhibits proliferation and induces apoptosis by regulating expression of microRNAs in human glioma U87MG cells. Int J Oncol. 2015;46(2):833–840. doi:10.3892/ijo.2014.2777
   PubMed Web of Science ®Google Scholar
• Weiger TM, Colombatto S, Kainz V, Heidegger W, Grillo MA, Hermann A. Potassium channel blockers quinidine and caesium halt cell proliferation in C6 glioma cells via a polyamine-dependent mechanism. Biochem Soc Trans. 2007;35(Pt 2):391–395. doi:10.1042/BST0350391
   PubMed Web of Science ®Google Scholar
• Utermark T, Alekov A, Lerche H, Abramowski V, Giovannini M, Hanemann CO. Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells. Cancer. 2003;97(8):1955–1962. doi:10.1002/cncr.11275
   PubMed Web of Science ®Google Scholar
• Lee SY, Rhee YH, Jeong SJ, et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol. 2011;26(4):424–431. doi:10.1002/tox.20568
   PubMed Web of Science ®Google Scholar
• Kimura O, Kondo Y, Shimosegawa T. PPAR could contribute to the pathogenesis of hepatocellular carcinoma. PPAR Res. 2012;2012:574180. doi:10.1155/2012/574180
   PubMed Web of Science ®Google Scholar
• Yu Q, Wu L, Ji J, et al. Gut microbiota, peroxisome proliferator-activated receptors, and hepatocellular carcinoma. J Hepatocell Carcinoma. 2020;7:271–288. doi:10.2147/JHC.S277870
   PubMed Web of Science ®Google Scholar
• Wu CW, Farrell GC, Yu J. Functional role of peroxisome-proliferator-activated receptor gamma in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27(11):1665–1669. doi:10.1111/j.1440-1746.2012.07213.x
   PubMed Web of Science ®Google Scholar
• Hsu HT, Sung MT, Lee CC, et al. Peroxisome proliferator-activated receptor gamma expression is inversely associated with macroscopic vascular invasion in human hepatocellular carcinoma. Int J Mol Sci. 2016;17(8):1226. doi:10.3390/ijms17081226
   PubMed Web of Science ®Google Scholar
• Tu K, Zheng X, Dou C, et al. MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma. Int J Mol Sci. 2014;15(11):20486–20499. doi:10.3390/ijms151120486
   PubMed Web of Science ®Google Scholar
• Xiao YB, Cai SH, Liu LL, Yang X, Yun JP. Decreased expression of peroxisome proliferator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma. Cancer Manag Res. 2018;10:1781–1789. doi:10.2147/CMAR.S166971
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041. doi:10.1002/hep.29904
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916–927. doi:10.1136/gutjnl-2018-316510
   PubMed Web of Science ®Google Scholar